No Carolina / New York / Florida        Ph: 561.316.3330

New Study Published in the New England Journal of Medicine Shows COVID-19 Causes Blood Vessel Damage

What To Know

  •   In the NEJM study, the researchers found an association between the more intussusceptive angiogenesis present, the longer the hospital stay of the patient suggesting that severity of COVID-19 disease is linked to blood vessel damage.
  • The new study published in the New England Journal of Medicine was conducted by an international team of medical scientists who compared the lungs of patients who died from COVID-19 with lungs of patients who died from influenza as well as with healthy lungs donated for transplantation.

New study published in the New England Journal of Medicine shows COVID-19 causes blood vessel damage. The Angiogenesis Foundation reports today that new research published in the New England Journal of Medicine shows that the respiratory virus SARS-CoV-2, which causes COVID-19, causes severe damage to blood vessels, leading to widespread thrombosis, or blood clotting, in the lung1.

The new study published in the New England Journal of Medicine was conducted by an international team of medical scientists who compared the lungs of patients who died from COVID-19 with lungs of patients who died from influenza as well as with healthy lungs donated for transplantation.  These researchers discovered an unexpected disease pattern in COVID-19 lungs: The virus invaded the cells that line blood vessels, called endothelial cells, and this was accompanied by blood clots. Compared to the flu, COVID-19 lungs had 9-fold more blood clots and the blood vessels were injured by the virus causing an unusual reaction of blood vessel growth.

“One of the great mysteries of COVID-19 has been why blood clots, or thrombosis, form in some patients who are infected,” said Dr. William Li, President and Medical Director of the Angiogenesis Foundation. “These clots can become lethal because they severely compromise blood flow not only in the lungs, but also in other organs such as the brain and heart, among other tissues.  Our research is the first to show that these clots are associated with damaged blood vessels.  The damage causes a unique healing reaction called intussusceptive angiogenesis that was found in COVID-19 at levels 30-times above normal.”

Scientists first described this phenomenon in the early 1990s as a way that blood vessels respond to injury by creating a new network of healing blood vessels2.  In the NEJM study, the researchers found an association between the more intussusceptive angiogenesis present, the longer the hospital stay of the patient suggesting that severity of COVID-19 disease is linked to blood vessel damage.  Intense inflammation was also found in all COVID-19 lungs.

“Although SARS-Cov-2 is a respiratory virus, we now see it can cause a vascular disease in COVID-19,” said Li. “The intussusceptive angiogenesis is how the body compensates when faced with thrombosis and blood vessel damage.” The injured blood vessel lining helps to explain the serious blood clotting observed in patients.  This damage may also underlie other problems seen with COVID-19, such as stroke, deep vein thrombosis, COVID toe, and damage to the heart, and also explain why anticoagulation may be helpful in preventing serious complications.  Separately, a May 6 report published in the Journal of the American College of Cardiology described how using blood thinners in patients hospitalized with COVID-19 appeared to be protective and associated with better outcomes3.

The current study highlights the need for additional research on angiogenesis and the vascular effects of COVID-19. “Our blood vessels are the lifelines for all of our organs,” said Li. “If COVID-19 damages our vessels, the long-term effects could be devastating even after the virus is cleared. Finding ways to protect our blood vessels and helping them heal could be an important dimension to COVID-19 treatment.  These interventions could involve not only medications, but importantly, dietary factors and lifestyle.”

In addition to the Angiogenesis Foundation, the following institutions were involved in this research:  Harvard Medical School (Boston); University Hospital Basel (Basel, Switzerland); KU Leuven (Leuven, Belgium), German Center for Lung Research and Hanover Medical School (Hannover, Germany); Helios University, University of Witten-Herdecke, and Johannes Gutenberg University of Mainz (Mainz, Germany).


1. Ackermann M, et. al.  Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. New Engl J Med 2020 (May 21, 2020)

2. Burri PH. Intussusceptive microvascular growth, a new mechanism of capillary network formation. EXS 1992;61:32-9.

3. Paranjpe I, et. al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020 May 5;S0735-1097(20)35218-9.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

"The programs selected for an AAOS IDEA Grant will help to cultivate meaningful and measurable opportunities across orthopaedics, acting as a springboard for change within our profession," said AAOS Diversity Advisory Board Chair Holly Tyler-Paris Pilson, MD, FAAOS, FAOA. "This is not about checking a box; this call for proposals opens a door for funding directly to the local and regional orthopaedic programs and organizations who are training the current and next generation."
In a 10-center study, microwave ablation offered progression-free survival rates and fewer complications than surgery in the treatment of a form of thyroid cancer known as papillary thyroid carcinoma (PTC), according to research published today in Radiology, a journal of the Radiological Society of North America (RSNA).
Robert J. Lewandowski said, “Throughout the last 50 years, SIR has enabled the specialty to grow in an evolving healthcare landscape, providing IRs with the education, resources, and support required for members to thrive. As we look forward, SIR remains committed to fostering healthcare innovations that improve patients’ lives worldwide.”
The ACC has selected 50 learners for its 2024 – 2025 Clinical Trials Research program, of whom 28 structural heart cardiologists and surgeons will participate in the CTR’s new Project REACH. This incoming cohort of learners will participate in a year-long curriculum designed to advance their skills and careers in clinical trials research and ensure that all individuals have the opportunity to contribute as part of the clinical trials research workforce.
Radiology Advances joins RSNA’s suite of peer-reviewed journals that includes the Society’s flagship journal, Radiology, education journal, RadioGraphics, and subspecialty journals, Radiology: Artificial Intelligence, Radiology: Cardiothoracic Imaging and Radiology: Imaging Cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy